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Abstract
Chronic migraine as a disease was initially recognized in patients with a large
burden of disability from frequent headaches and a history of prior migraines. Over
time, this observation was operationalized into multiple diagnostic criteria with
requirements for frequent headache days, typically 15 or more, which, on at least
8 days in a month, have the features of migraine headache. Chronic migraine affects
1–2% of the general population, and about 8% of patients with migraine. Under-
standing disease mechanisms still remains a challenge. Inflammation and central
sensitization play significant role in the evolutive mechanisms of chronic migraine.
Treatment of this condition should primarily focus on the prevention. The currently
available evidence-based prophylactic treatment options are topiramate, valproic
acid, onabotulinumtoxin A and recently developed promising anti-CGRP monoclo-
nal antibodies. Chronic migraine research is a dynamic and rapidly advancing area.
New developments in this field have the potential to improve the diagnosis, to
provide more personalized treatments and to reduce burden of disability.
Keywords: chronic migraine, epidemiology, pathophysiology, risk factors,
symptoms, diagnosis, treatment, prevention
1. Introduction
Chronic migraine (CM) is a distinct and relatively recently defined type of
migraine initially recognized in patients with a large burden of disability from
frequent headaches and a history of prior migraine.
The International Headache Society (IHS) defines CM as more than 15 headache
days per month over a 3-month period of which more than eight are migrainous [1].
Disability rates and burden of disease among individuals with CM has more-
severe impact on socioeconomic functioning and quality of life than does episodic
migraine (EM) [2–4]. About 25% patients with CM report a very severe headache-
related disability, as defined by the Migraine Disability Assessment Scale (MIDAS)
to compare with 3% of patients with EM [2]. The proportion of patients with CM
who report reduced household productivity, missed family activities and missed
household work is two to three times higher than that of EM patients [4]. The
annual per-person costs of CM—consisting of direct costs caused by health care
utilization and treatment expenses (30%) and indirect costs attributable to
absenteeism from work and loss of productivity (70%)—are about fourfold higher
than those concerning with EM [5, 6].
Acknowledgment the severe effect of CM on socioeconomic functioning and
quality of life, effective treatment of this disorder and preventing progression from
episodic to CM—are one of most important problems in management of headache
disorders.
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2. History
The current definition of CM as outlined in the International Classification of
Headache Disorders, 3rd edition (ICHD-3) [1] is relatively new. This definition has
been tested multiple times and has gone through multiple revisions.
Although migraine as a distinct condition of headache with other accompanying
symptoms has been known for thousands of years from the early writings of
Aretaeus of Cappadocia in 30–90 A.D. [7]. The first formal modern definition of
migraine was outlined in 1962 [8]. This first definition did not contain operational
rules for migraine diagnosis and in 1988 the IHS published operational diagnostic
criteria entitled the International Classification of Headache Disorders (ICHD-1)
[9]. Criticism has been raised by experts that the ICHD-1 was not comprehensive
enough to introduce diagnostic criteria for chronic headaches [10].
It was recognized in the 1980s that a chronic frequent headache patient population
had a history of migraine [11, 12]. The daily and near daily headache patients were
classified with multiple diagnoses but likely represented a single pathophysiological
entity of migraine transformation with increased frequency. Recognizing this draw-
back, the Silberstein—Lipton criteria 1994, 1996 were proposed [13, 14]. They stipu-
lated that chronic daily headaches defined as headaches on 15 or more days a month
for at least 1 month, there was a subcategory of transformed migraine (TM) [6].
The term chronic migraine the first time in the literature was used by Manzoni
et al. [15]. The results of a population study of chronic daily headache patients in Italy
showed that 72% had fulfilled an IHS diagnosis of migraine [15]. For the first time CM
appeared in the International Classification of Headache Disorders, 2nd edition
(ICHD-2), 2004 [16]. There the CM category was defined as a complication of
migraine, in patients having migraine without aura on at least 15 days per month, for
at least 3 months, before the diagnosis was established. In the comments were stated
that chronicity may be regarded as complication of EM and if medication overuse is
present this is the most likely cause of chronic symptoms and it was suggested to code
probable CM and probable medication- overuse headache (MOH). The requirement
of having 15 migraine days per month was likely too stringent [17] and in a field trial
of the ICHD-2 criteria [18] only 5.6% could be classified with CM, and only 10% could
be classified to probable migraine with probable MOH.
Further, as it was recognized in prior studies, in the process of migraine trans-
formation or chronification, the migraine features of some of the headaches may be
lost [11–14].
Recognizing the drawbacks, in an appendix to ICHD-2R the CM definition was
specified by requiring only 8 days per month to meet the definition of migraine or
be responsive to migraine specific medications. This criterion is still present in the
ICHD-3 [1].
ICHD-3 criteria of CM include a mixture of migraine and tension-type-like
headaches and do not account for patients with high-frequency migraine attacks in
the absence of other types of headaches [19].
Patients with migraine on eight or more days but not 15 days with headache a
month are as disabled as patients with ICHD-3 defined CM [19]. Following this data
a criticism regarding the existing CM criteria was raised and suggestion to revise the
CM criteria was iniciated [19].
3. Epidemiology
The prevalence of CM worlwide ranges is reported to be between 0.9–5% [20],
in a general population, and about 8% among patients with migraine [2, 21–24].
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However, the true prevalence of CM is difficult to estimate because of heterogeneus
data collection instruments.
CM accounts for about one-third of chronic headache (with more than 180 days
per year) in general population [23]. This headache disorder is almost three times
more common in women than in men with prevalence rate peaks at the ages of
18–29 years with repeating at 40–49 years [2, 22]. Most studies suggest that annu-
ally, from about 2.5% of people with EM evolves CM [25, 26], while only a limited
portion with CM revert back to EM [25, 27].
The course of CM can change—spontaneous or medically induced remission is
possible. About 26% of patients can experience remission within 2 years of the onset
of CM [24]. Large-scale epidemiological studies have identified various factors
associated with progression from episodic to CM, and also factors that promote
migraine remission [27].
Most important nonmodifiable risk factors for migraine chronification are age,
female sex and low educational status [2, 7, 14, 23]. Individuals with CM have
increased incidence of certain somatic and psychiatric comorbidities—in compari-
son with people with EM [23, 25]. However, the understanding of complex factors
and mechanisms leading to an increased migraine frequency and consequently to
the development of CM are only in the beginning and needs further investigations.
4. Pathophysiology
Generally the pathophysiology of migraine is intricate and in spite of substantial
progress in recognizing its mechanisms over the past several decades, it still remains
not fully elucidated. Even more, so is the pathophysiology of CM. Current evidence
defines migraine as a disorder of brain dysfunction with genetic background and
environmental triggering [28]. To date there is limited number of scientific studies
exploring the chronic form of migraine, therefore the reasons why the disease
sometimes takes a turn and attacks become more frequent are not fully clarified yet.
The key components proposed in the pathogenesis of migraine chronification
include atypical pain processing, central sensitization, cortical hyperexcitability and
neurogenic inflammation [29] (Figure 1).
Distinct phases of migraine are associated with different anatomical areas and
driven by different processes. Prodromal symptoms that can develop prior the onset
of migraine pain are believed to be a result of abnormal activity in cortical, dience-
phalic and/or brainstem areas. Migraine aura, experienced by approximately one
third of patients, is most probably caused by cortical spreading depression (CSD)—
a phenomenon defined as a slowly propagating depolarization wave followed by a
prolonged period of inhibition of cortical activity [28, 30]. Going further, the
pivotal process of the headache phase is activation of the trigeminovascular system.
As the brain itself has been known to be rather insensate, the intracranial nocicep-
tive impulses are generated in pain-sensitive structures like pial, arachnoid and
dural blood vessels, venous sinuses as well as large cerebral arteries, all of which are
innervated by nociceptive nerve fibers originating in the trigeminal ganglion. Acti-
vation of these structures by various stimuli is responsible for generation of
migrainous pain and its associated features [31–33]. Extracranial afferent nocicep-
tive innervation is largely received through the divisions of trigeminal nerve,
mainly the ophthalmic, as well as the upper cervical dorsal root ganglia [34]. The
intracranial and extracranial neural afferents enter caudal medulla via trigeminal
tract and terminate in the spinal trigeminal nucleus caudalis and upper cervical
spinal cord (C1-C3)—the trigeminocervical complex (TCC) [35, 36]. Next, the
nociceptive information travels further via ascending pathways to the diencephalon
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and cortical areas, including insula and cingulate cortex. [28] The role of the limbic
system is also significant: central pain processing and further relaying of sensory
information depend largely on the thalamus [28, 37]; moreover, the amygdala and
hippocampus participate in affective and cognitive perception of pain [38, 39]—
features contributing to migraine notoriety as a disabling and burden-causing dis-
ease with strong emotional implications.
Under normal physiological circumstances activation of the nociceptive system
is counterbalanced by pain modulation. It is known that in migraine, descending
pain-modulating pathways are dysfunctional and pain inhibition is atypical, there-
fore susceptibility to migraine attacks is increased [40, 41]. Modulation system
originates in the cerebral cortex and is carried out via cortico-trigeminal pathways
with participation of brain structures, such as hypothalamus, locus coeruleus,
nucleus raphe magnus and rostral ventromedial medulla. A core structure control-
ling pain and providing endogenous analgaesia is the periaqueductal gray matter
(PAG) [42, 43]. Due to repetitive migraine attacks and prolonged exposure to pain,
PAG and other structures, comprising the descending pain-modulating network,
are excessively activated, which results in oxidative stress and subsequent dysfunc-
tion. Thereby adequate pain modulation is not ensured and susceptibility to gener-
ation of migraine attacks increases [42–44].
Some authors propose that migraine chronification can be seen as a threshold
problem [45]. Pain threshold exists in order to protect from situations where daily
non-noxious stimuli could induce pain, therefore it takes a stimulus of certain
potency to actually be perceived as painful. Pain threshold is inconstant and shifts
depending on cyclic changes that are thought to originate in the limbic system [46].
Those changes allow threshold fluctuations making individuals periodically more
Figure 1.
Components of pathogenesis of migraine chronification. Data from Ref. [29].
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susceptible to migraine attacks. During the interictal period threshold is normal, but
when it decreases sufficiently, certain events, like stress or changes in hormonal or
sleep rhythm, can provoke a migraine attack [47, 48]. Frequent attacks are among
the major risk factors of migraine chronification, as they shorten the interictal
period thus preventing restoration of the pain threshold to normal level [27, 49].
Consequently the sensory threshold stays below-baseline for most of the time and
susceptibility to migraine attacks increases. Likewise, the most common risk fac-
tors, as obesity, physical inactivity, psychiatric illnesses and stress, might affect the
threshold and make individuals more prone to migraine episodes [45].
Further alteration of pain threshold and increased sensitivity to attack-inducing
triggers can be influenced by central sensitization [45]. Cutaneous allodynia, which
represents central sensitization, is significantly more prevalent in chronic migraine
patients than those with episodic one, suggesting that frequent attacks and higher
pain intensity contribute to the development of central sensitization [50, 51]. This
also explains why ineffective attack management is a risk factor for chronification:
if migraine attacks are not treated completely, it results in a longer and more intense
state of pain, leading to pronounced central sensitization, lowered pain threshold
and increased susceptibility to migraine transformation [50, 52]. Overuse of acute
pain medications is another risk factor for migraine progression, as it has been
shown to promote central sensitization and susceptibility to CSD [27, 53].
There has been increasing evidence on altered cortical excitability in migraine
[54]. Studies with transcranial magnetic stimulation have demonstrated reduced
visual suppression in CM patients compared with EM patients and healthy controls,
which proves the presence of cortical hyperexcitability [42]. In addition, assess-
ment of visual evoked potentials shows that interictal excitability of the visual
cortex is persistent and matches that of a migraine attack thus creates a “never-
ending” migraine [55]. The underlying mechanisms of cortical hyperexcitability
have not been uncovered yet, but evidence suggests that it may be induced by
dysfunction of the pain modulatory pathways [55].
Another contributor to the pathophysiology of CM is neurogenic inflammation
[29, 56]. Upon nociceptive stimulation by chemical, mechanical or electrical stim-
uli, a number of vasoactive substances are released from the axon terminals, causing
vasodilation of the blood vessels and further plasma extravasation, edema and
mastocyte degranulation. This so-called “sterile inflammation” results in sensitiza-
tion and activation of the trigeminal meningeal receptors [28, 56], promoting the
induction of migrainous pain [56]. Among the best-studdied vasoactive substances
are calcitonine gene-related peptide (CGRP), substance P, neurokinin A, serotonin
(5-HT) and pituitary adenylate cyclase-activating peptide (PACAP). CGRP is one of
the most significant central pronociceptive agents expressed in the trigemino-
vascular system and associated with pain processing and migraine symptoms. It
takes part in the development of peripheral and central sensitization and enhanced
abnormal pain perception [28]. Vasoactive intestinal peptide (VIP) is another
important parasympathetic neurotransmitter with a headache-eliciting effect
[57, 58]. These pro-inflammatory vasoactive substances have been in the spotlight
of research for years with regard to their potential role as biomarkers for chronic
migraine. The levels of CGRP and VIP have been measured and compared during
the interictal state of episodic and chronic migraine, showing an increase of either in
the latter [59]. This provides additional evidence on altered interictal activity of the
trigeminovascular system in chronic migraineurs. Moreover, the role of other sub-
stances, such as leptin, adipoleptin, TNF-α and glutamate, in the processes related
with persistence and progression of migraine, has been demonstrated. This provides
reasonable hopes on future implementation of biomarkers for migraine
chronification [57, 58, 60].
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In terms of anatomic changes in migraine, white matter lesions are considered to
be more common in migraineurs than in general population. Moreover, increase in
lesions correlates with attack frequency [61]. Recent neuroimaging studies revealed
some other neuroanatomical differences correlating with headache frequency that
could even be considered indirect markers of migraine chronification: it showed
that migraineurs with more frequent attacks had thicker somatosensory cortex,
anterior cingulate cortex and inferior temporal gyrus, compared with those with
low-frequency attacks [62]. Also correlation with thickness of left middle frontal
gyrus and left central sulcus was noted. Moreover, patients with CM had volumetric
changes in amygdala, hippocampus, putamen and brainstem areas [63]. These data
once again prove the role of these cerebral structures in the pathogenesis of chronic
migraine [64].
Genetic influence on the progression from episodic to CM is yet to be established
as more large-sample studies are needed [64, 65]. However it looks that chronic
migrain has a polygenetic background. Data suggest the role of certain gene groups
linked to migraine and pain progression, addiction and medication overuse,
hyperexcitability and oxidative stress in migraine chronification [66]. Furthermore,
it is becoming clear that epigenetics is also related to migraine as to many other
multifactorial diseases. Although to date there are no specific genetic studies in
chronic migraine patients, there is some evidence that neuronal activity occuring
during CSD may cause epigenetic changes involved in neuronal plasticity,
neuroprotection and regulation of basal synaptic activity [67, 68].
5. Risk factors
Not all patients with EM progress into chronic form [69]. The American
Migraine Prevalence and Prevention (AMPP) Study [70], the International Burden
of Migraine Study (IBMS) [3] and the others have explored at the prevalence of
different features in episodic and CM. Some of them have been found to be more
prevalent in the chronic form of migraine, suggesting that these features should be
seen as risk factors associated with migraine conversion that may serve as prognos-
tic markers enabling prediction of possible migraine progression from episodic to
chronic form. Knowing these factors can assist in identifying patients at risk of
transformation and take appropriate measures to prevent it (Table 1).
The risk factors can be divided into non-modifiable and modifiable. Some of
them carry more weight in predisposing CM than the others do. The most signifi-
cant risk factors are overuse of acute medication [27], ineffective acute treatment
[51], obesity [71], depression [72] and stressful life events [27]. The risk factors are
listed in Table 1.
Studies show that higher prevalence of CM is related to some non-modifiable
demographic characteristics, such as female sex [73, 74] and Caucasian race [75].
Regarding age, CM tends to be increasingly more prevalent from 18 to 50 years in
both sexes [2]. In terms of the modifiable risk factors, there is evidence for
correlation between lower level of education and CM, but data are inconsistent
[3, 24, 25, 75]. In addition, some studies propose lower economic status [76],
being unmarried [25] and unemployed [3, 25] as risk factors for chronic
migraine.
Some modifiable lifestyle features have also been listed as risk factors of CM.
First, high caffeine intake is connected with migraine transformation, especially
when excessive consumption has started before the onset of chronic daily headache
[77]. Second, obesity, especially in women, is more prevalent in chronic than in EM
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thus it can be considered a risk factor for migraine chronification [71]. In fact,
similar relation also exists between increased body weight and other headache
disorders like MOH and benign intracranial hypertension [78–79]. The mechanisms
linking obesity and frequent headaches are not known yet, but it may be related to
hyperleptinemia [80–82]. Next, sleep disorders, including sleep apnea, snoring,
disturbed sleep and oversleeping, have been found to elevate the risk for developing
CM [83, 84]. Therefore it is obvious that patient education and counseling on
lifestyle is extremely important, as reducing caffeine intake, normalizing body
weight and sleeping patterns early enough may help to prevent migraine
progression.
Another tendency is that patients with CM report various comorbidities more
commonly than those with CM. According to the CaMEO study, patients with the
most comorbidities were 5 times more likely to progress to CM than those with the
fewest [84, 85]. Psychiatric comorbidities, especially anxiety and severe or moder-
ate depression, are particularly prevalent in CM patients [72, 84, 86] as are some
personality traits and disorders, in particular obsessive-compulsive, dependent,
avoidant and passive-aggressive [87]. Chronic pain conditions, including fibromy-
algia, chronic back and neck pain, are also a strong prognostic factor for migraine
progression from episodic to chronic state as they are much more commonly
reported by chronic migraineurs [88]. Other comorbidities such as cardiovascular
disorders, asthma and allergies [25] are also considered risk factors for migraine
progression. Moreover, various major life changes, like divorce, change of employ-
ment status or being recently widowed also play a role in migraine conversion,
partially by accompaniment of anxiety and depression [27]. Therefore it is critically
Demographic characteristics Treatment-related factors
Female sex
Caucasian race
Increasing age
Lower level of education
Lower economic status
Being unmarried
Unemployment
Acute medication overuse
Insufficient treatment
Comorbidities
Psychiatric disorders
Depression
Anxiety
Bipolar disorder
Personality disorders and traits
Obsessive-compulsive
Avoidant
Dependent
Passive-aggressive
Concomitant chronic pain disorders
Fibromyalgia
Back and neck pain
Painful neuropathy
Cardiovascular disorders
Arterial hypertension
Hypercholesterolemia
Asthma
Stress related with major life changes
Divorce
Change of employment status
Grief
Lifestyle factors
High caffeine consumption
Obesity
Sleep disorders
Sleep apnea
Snoring
Sleep deprivation
Excessive sleeping
Headache features
Frequent attacks
Cutaneous allodynia
Table 1.
Risk factors for chronic migraine [27, 51, 71, 72].
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important to adequately treat these comorbidities in order to prevent migraine
chronification, impaired quality of life and development of disability.
In addition to what has been set out before, some headache features have been
established as risk factors too. One of the majors is headache frequency [27, 69].
Scher et al. has shown that the risk for chronification increases with the increase of
headache frequency in a non-linear fashion. A minimum of three attacks per month
is enough to elevate the risk for new-onset chronic headache [27]. This is based on
the fact that prolonged exposure to pain induces central sensitization and decreases
the attack threshold. Hence this once again emphasizes the importance of rapid and
adequate treatment of migraine attacks to prevent pathophysiological alterations
leading to migraine chronification.
Another specific clinical feature of migraine attack is cutaneous allodynia, which
affects approximately 63% of migraineurs [89]. According to Burstein et al. and
Louter et al. it is not only a clinical marker of central sensitization but can also be
considered an independent predictor of migraine chronification [50, 52]. From
therapeutic point of view, triptans should be administered to terminate a migraine
attack within 30 minutes for subjects with cutaneous allodynia in order to minimize
exposure to pathological processes leading to migraine chronification [90].
Aditionally some treatment-related factors are proven to play a role in the
pathogenesis of CM. The Akershus study [91] among other data has confirmed that
acute medication overuse has substantial impact to the processes leading to
migraine progression. Acute medication overuse is defined as medication intake on
10–15 days per month [92]. Among the different analgesic groups opioids, barbitu-
rates and combination drugs are associated with the highest dose-dependent risk,
while triptans show moderate association with migraine progression and it is more
likely in patients with higher baseline attack frequency. Interestingly, some data
reports protective effect of NSAIDs against migraine progression, but only in
patients with less than 10 attacks per month [79, 92]. The impact of medication
overuse in migraine progression is supported by the fact, that attack frequency and
disability decreases after discontinuation of acute medication, which also allows
more effective preventive treatment [91].
On the other hand, the AMPP study states that ineffective or insufficient treat-
ment can also promote chronification processes [90]. Patients using triptans are
more likely to successfully abort the attacks than those using NSAIDs and simple
analgesics therefore they are at less risk for chronification [51].
In conclusion it is crucial that effort is made to treat migraine attacks rapidly and
adequately as well as to modify other risk factors relevant to the patient so that the
pathophysiological mechanisms responsible for migraine progression from episodic
into chronic form could be precluded [45, 64].
6. Symptoms and diagnosis
Although the most obvious difference between episodic and CM seems to be the
frequency of attacks, clinical migraine features may change too as the disease pro-
gresses from less frequent to chronic form. Usually over time the pain becomes
more “featureless”, thus resembling tension-type headache for most of the time
with some more prominent migraine-like attacks interjected [69].
Typical migraine attacks generally manifest as severe, usually unilateral head-
ache of throbbing quality, increasing intensity with physical activity and a combi-
nation of associated features: nausea, vomiting, hypersensitivity to visual, auditory,
olfactory and cutaneous stimuli. The headache can change sides during or between
the attacks [64]. The pain in patients with CM is more commonly bilateral and the
8
Migraine
associated symptoms are less pronounced than in those with EM [93]. Some
patients report prodromal symptoms up to 48 hours before the onset of pain,
including fatigue, asthenia, impaired concentration, irritability and other that can
warn against an upcoming attack. However, it can be difficult to distinguish pro-
dromal periods in CM as the attacks are very frequent or continuous [24].
Migraine with aura affects 20–40% of all migraineurs [93] and features a selec-
tion of transient focal neurological symptoms that usually but not invariably present
before the onset of pain. The most common aura type accounting for approximately
90% is visual [84], but patients can also experience sensory, brainstem or
hemiplegia-related aura [69, 84, 94]. Both types of migraine, with and without
aura, can progress into chronic form.
According to the newest ICHD-3 criteria (Table 2), CM should be diagnosed when
headache is experienced on 15 or more days per month over more than 3 months. The
headache on 8 or more days per month should meet the criteria for migraine with or
without aura and/or should be relieved by specific migraine treatment [1].
Not always it is easy for the patients to remember the exact number of days of
pain per month, hence keeping a headache diary can come to help. Patients should
be encouraged to not only mark the days of pain, but also elaborate what the pain
was like, what features it was accompanied by, was any medication required and
with what outcome. This is a good and easy tool for a physician to not only accu-
rately know the count up of the headache days, but also make a full picture of its
characteristics [95, 96].
Physician making a diagnosis should obtain a detailed history, as history is where
the diagnosis of migraine lies. A thorough neurological examination, including
fundoscopy, should be the following step during consultation [97].
In case of presentation of typical features of CM and normal examination, no
further testing is required. However vigilance is needed to suspect any possible
secondary headache causes, such as infections, tumors or hydrocephalus (Table 3),
when additional investigation is warranted [29]. The set of tests required depends
on clinician’s judgment in each situation and may include certain blood tests, imag-
ing of brain, cervical spine and sinuses, scanning of cranial and extracranial arteries
and performing a lumbar puncture with measuring of the CSF opening pressure.
The method of choice for brain imaging is usually MRI [97]. The most consistent
indicators for such conditions (“red flags”) include thunderclap headache, associ-
ated focal neurological deficit or systemic features, headache of onset in patients
over the age of 50 years and more [29, 97–99].
After stating that the patient has a primary headache disorder, the pattern of the
headache should be established. Episodic headache occurs on less than 15 days per
month while chronic headache—on 15 or more days in a month. Headaches lasting
up to 4 hours are considered “short” in contrast to “long” headaches that last more
A. Headache (migraine-like or tension-type-like) on ≥15 days/month for >3 months, and fulfilling
criteria B and C;
B. Occurring in a patient who has had at least five attacks fulfilling criteria B-D for 1.1Migraine without
aura and/or criteria B and C for 1.2Migraine with aura;
C. On ≥8 days/month for >3 months, fulfilling any of the following:
1. Criteria C and D for 1.1 Migraine without aura;
2. Criteria B and C for 1.2Migraine with aura;
3. Believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative;
D. Not better accounted for by another ICHD-3 diagnosis.
Table 2.
Chronic migraine diagnostic criteria, ICHD-3, 2018.
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than 4 hours [100]. CM should be differentiated from other chronic long-duration
primary headaches (Table 3). Hemicrania continua is strictly unilateral continuous
headache condition with superimposed exacerbations of pain that display ipsilateral
autonomic symptoms. CM can also present with autonomic features, but they are
much less pronounced. In addition to this, hemicrania continua features a
distinguishing absolute responsiveness to indomethacin which is a key factor in
differential diagnosis [29]. Chronic tension-type headache usually manifests as
bilateral ache of non-throbbing quality and mild to moderate severity, while CM
can be unilateral or bilateral and of moderate to severe intensity. Importantly,
chronic tension-type headache is considered “featureless”—it is not usually accom-
panied by migrainous symptoms like nausea, vomiting, photophobia, phonophobia,
and is not exacerbated by exertion. As migraine progresses into chronic form, the
headache may resemble tension-type on some days [29]; nonetheless, typical
migraine features must be present on at least 8 days per month for the diagnosis of
chronic migraine to be validated [1].
The main feature of new daily persistent headache is a distinct and clearly
remembered onset and rapid development to an unremitting state of pain over
24 hours. This distinguishes it from chronic migraine that develops slowly over the
course of months or years while attacks become more and more frequent and
merged together. Besides, the localization and accompanying symptoms of new
daily persistent headache are usually undefined and nonspecific, thus alleviating the
differential diagnosis [29, 45, 97].
Another point to remember is the importance of assessing the patient for possi-
ble acute medication overuse, as it is one of the major risk factors for migraine
progression. Sometimes it may be challenging to tell if medication overuse is a cause
or a consequence of CM. The ICHD-3 criteria encourage coding both CM and MOH
diagnoses in case when medication overuse is confirmed [1]. The diagnoses should
be reviewed and specified later after assessing the effect of medication withdrawal:
the headache may revert to episodic migraine or remain chronic. The former case
would suggest that medication overuse indeed was a causative factor that had led to
chronification. In the latter scenario the diagnosis of medication-overuse headache
Etiology Examples
Anatomic
disorders
Cervical pain, temporomandibular joint disorders, myofascial pain
Changes in
intracranial
pressure
Intracranial
hypertension
Tumor, hemorrhage, brain infection, primary benign intracranial
hypertension, hydrocephalus, pituitary apoplexy
Intracranial
hypotension
Post-lumbar puncture, post-epidural/spinal analgesia, spontaneous
CSF leak
Infection Meningitis, encephalitis, sinusitis, abscess
Medication and substance
disuse
Medication overuse headache, medication side-effects, substance
abuse or withdrawal
Metabolic disorders Uremia, hepatic encephalopathy, hypoxia
Neuralgias Trigeminal neuralgia, occipital neuralgia
Psychiatric Somatoform disorder, psychosis, aggravation
Trauma Traumatic brain injury
Vascular disorders Stroke, dissection of carotid or vertebral arteries, giant-cell arteritis,
arterial hypertension, CADASIL, venous sinuses thrombosis
Table 3.
Possible Causes of Secondary Headaches (alphabetically ordered) [29, 45, 97].
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should be revoked, as it would seem that the overuse had taken place simply as a
result of increased attack frequency [101]. Points of the differential diagnosis are
summarized in Table 4.
Once the diagnosis of CM has been confirmed, standard questionnaires, such as
Migraine Disability Assessment (MIDAS) or Headache Impact Test-6 (HIT-6)
should be used for patient assessment in order to evaluate the burden of disease and
monitor the effects of prescribed treatment [95]. Episodic and treatment-responsive
migraine can be diagnosed and managed in the primary care, while chronic or
refractory patients should be referred to a specialist neurologist, preferably with an
expertise in the field of headache disorders [95].
7. Treatment
There are three broad approaches to treating CM [97]:
• Lifestyle and trigger management.
Headache
type/
causative
problem
Localization Duration Associated and
distinguishing
features
Diagnostic
tests
Chronic
migraine
Unilateral or bilateral • Hours to days
or continuous
• Headache
present on at
least 15 days
per month
• Throbbing
nature
• Accompanying
nausea,
vomiting,
photophobia,
phonophobia
• Exertional
exacerbation
ICH-3 criteria
Hemicrania
continua
Side-locked • Daily,
continuous
pain with
superimposed
exacerbations
• Ipsilateral
autonomic
features
• Indomethacin-
responsiveness
ICH-3 criteria
Indomethacin
trial [12]
Chronic
tension-
type
headache
Usually bilateral, but can be
unilateral
• Hours to days
or continuous
• “Featureless”—
no or rare
accompanying
symptoms
ICH-3 criteria
Medication
overuse
headache
Undefined • Hours to days
or continuous
• History of acute
medication
overuse
• Improved after
withdrawal
ICH-3 criteria
New daily
persistent
headache
Daily persistent headache with
a distinct and clearly
remembered onset, with pain
becoming continuous and
unremitting within 24 hours
Undefined Undefined Individual
approach:
• Brain
imaging
(CT, MRI)
• Lumbar
puncture
• Blood tests
*Data from Refs. [29, 45, 97].
Table 4.
Differential diagnosis for long-duration primary headaches*.
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• Acute headache treatments.
• Preventive treatment.
7.1 Lifestyle and trigger management
Lifestyle modification, as well as trigger reduction can, be helpful in reducing
the fequency of migraine attacks and stopping or slowing down the process of
migraine chronification. That includes regularity of regimen with regard to meals,
hydration, sleep and stress. It could be also helpful to detect and understand the
obvious triggers. It is important to know other problems that exacerbate the ten-
dency to headaches: such as: depression, anxiety, other pain syndromes such as
fibromyalgia, localized pain in head and neck structures, and conditions that create
‘metabolic’ strain such as obesity, sleep apnoea or postural orthostatic tachycardia
syndrome [102, 103]. It is particularly important to recognize and manage medica-
tion overuse (including caffeine overuse), as failure to do so will render most
attempts at preventive treatment ineffective [92].
In order to identify the factors mentioned above it is very important to take a
detailed history of the particular patient and to evaluate the headache question-
naires and diaries, which are suggestable in many headache centers worldwide.
7.2 Acute headache treatments
The natural course of CM presents a variation in headache frequency meaning
that patients can fluctuate between EM and CM [97] and exacerbations of chronic
pain. Acute CM treatments are necessary to treat these conditions; e.g., migraine
attacks or exacerbations of chronic pain.
For the patients with CM often is difficult to know when to take acute treat-
ments. The physician should discuss this question with the patient and also explain
about the possibility of co-existence of MOH, which now is considered a sequela
rather than a cause of migraine and can co-exist with CM [1, 92].
In order to prevent the development of MOH, it is very important to avoid using
painkillers and triptans too often in the early stages of management [104]. The
detailed anamnesis and analysis of patient headache questionnaire and diary will
help to understand and count the” good days and bad days “or the days with clearly
exacerbated headaches. For the acute headache treatment are recommended the
same groups of medications as for migraine attack treatment. This includes simple
analgesics, combinated analgetics, triptans if the analgetics are not effective, and
neuromodulating procedures [97, 99, 105] (Reference to section on treatment of
migraine attacks to be included).
Opioids are not recommended for the treatment of acute headache because of
the significant risk of medication overuse and the most protracted withdrawal [106].
Triptans are migraine-specific medications that inhibit the release of CGRP by
activation of presynaptic 5HT1 receptors [107, 108]. However, patients should not
take triptans more than 10 days in a month to avoid developing MOH [1].
Non-invasive stimulation procedures could be used in patients who refuse to use
pharmacological migraine therapy or it is contraindicated or not tolerated. That
includes external trigeminal nerve stimulation [109], single transcranial magnetic
stimulation [110] and transcutaneus vagal nerve stimulation [111].
Effective acute treatment of migraine attacks may help to prevent progression
from EM to CM, but rather than relying on taking drugs to stop migraine attacks
after they have started, the aim of treatment for CM should be the prevention of
migraine attacks [20].
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7.3 Preventive treatment
The goals of CM prophylactic treatment are to prevent attacks, thereby reducing
headache frequency, severity and associated disability and decreasing reliance on
acute treatment, which may be contributing to concurrent MOH [92, 104]. An
additional goal may be to prevent progression of EM to CM in patients with high-
frequency attacks [45]. The first-line treatment of CM is pharmacological [45].
Numerous orally administered drugs are used for the prophylaxis of CM,
including beta-blockers, calcium-channel blockers, tricyclic antidepressants, sero-
tonin antagonists, antihypertensives, and antidepressants [112]. The drugs that are
effective for EM are not necessarily effective for CM [54], but evidence for the
efficacy of oral agents in CM is generally extrapolated from studies in patients with
high-frequency EM [97, 113]. Insufficient efficacy, not suitable route and dose of
drug administration and/or adverse events leading to treatment discontinuation
often occur with these drugs in patients with CM [114, 115].
The only currently available evidence-based prophylactic treatment options for
CM are topiramate and onabotulinumtoxinA (OBT-A) which is a formulation of
botulinum toxin A administered by intramuscular injection, from more than one
randomized controlled trial [97, 113].
7.3.1 OnabotulinumtoxinA
To date, OBT-A is the only treatment specifically approved for the prevention of
CM in the EU and North America (class of evidence I, level of recommendation A)
[116–119]. In the Phase III Research Evaluating Migraine Prophylaxis Therapy
(PREEMPT) trials [117, 118] OBT-A has been shown to be an effective and gener-
ally well tolerated treatment for the prevention of CM, and tends to be better
tolerated than various oral prophylactic treatments, including topiramate [120–123].
Based on the PREEMPT clinical trial protocol, OBT-A is administered to at least 31
injection sites across 7 head and neck muscles, and is currently recommended as a
second-line option for patients who have not responded adequately or are intolerant
of commonly prescribed oral migraine prophylaxis [124]. Treatment should be
repeated every 12 weeks. This data was confirmed in recently finished Chronic
migraine OnabotulinuMtoxinA Prolonged Efficacy open Label (COMPEL) study,
aim to investigate the long-term safety, efficacy and tolerability of nine cycles of
repetitive BoNT-A injections. The Compel Study concluded that OBT-A treatment
was well tolerated over 108 weeks, and no new safety signals were identified [125].
The molecular biological mechanism of action of OBT-A is well established,
whereby it inhibits fusion of intracellular vesicles with the nerve membrane [125]
by cleaving synaptosomal-associated protein (SNAP-25) [126, 127]. By impairing
intraneuronal vesicular fusion, OBT-A modulates neuropeptide release and
downregulates receptors and ion channels important in nociception [128, 129].
So, it is thought that OBT-A blocks release of CGRP from peripheral nociceptive
neurons and interferes with transient receptor potential cation (TRP) channels in
the trigeminally-innervated cranio-facial-cervical region, thereby reducing neuro-
nal hyperexcitability and peripheral and central sensitisation [54, 130]. It is
hypothesized that trigeminal-targeted preventative treatments counteract the
impingement of nociceptive input from highly sensitized trigeminal neurons on
brainstem second-order neurons, thus preventing central sensitisation, a key path-
ophysiological mechanism of CM [131].
Additionally recent clinical data demonstrates that OBT-A has been shown to
reduce serum CGRP concentration in patients with CM (pretreatment median,
74.1 pg/mL; 1 month post-treatment median, 51.9 pg/mL, P < 0.001) [132]. One
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month after treatment, CGRP levels significantly decreased in patients defined as
OBT-A responders.
There is no consensus in the literature regarding the number of OBT-A cycles
required for the preventive treatment of CM. Some trials suggest an increasing
efficacy with regular cycle repetition for more than 1 year, including in patients
with MOH (three class II trials, level B recommendation) [133–135]. To date, no
clinical features predicting responses to OBT-A (recommendation level B) have
been identified [136, 137].
The adverse effects of this treatment are rare, transient and mild. The most
frequently reported were neck and shoulder muscle weakness, post-application
headache, palpebral pseudoptosis and other facial mimics asymmetries, in addition
to pain at injection sites (class of evidence I) [117–119, 137–139].
7.3.2 Topiramate
Although not specifically licensed for CM, orally administered anticonvulsant
topiramate is an effective prophylactic treatment for patients with migraine, and
may be effective in patients with CM [140]. Topiramate reduced headache days
versus placebo and was relatively well tolerated in patients with CM in two large
randomized controlled trials [141, 142]. The initial dosage should be started slowly
with 2  12.5 mg or 2  25 mg and a dose of 2  50 mg (if necessary up to 2  100
mg) per day as final target dose. Adverse events commonly associated with
topiramate include paresthesia, memory and concentration disturbances, fatigue,
nausea, and weight loss [143, 144].
It is thought that topiramate has dual effects on neurotransmission—enhancing
inhibitory effects while minimizing excitatory effects, both of which are implicated
in migraine physiology [145]. The pharmacologic mechanisms underlying this
antimigraine activity may include blockade of cell membrane ion channels and
neurotransmitter release (e.g., inhibition of glutamate), resulting in inhibition of
neuronal hyperexcitability. Studies have demonstrated topiramate’s inhibitory
effect on excitability in motor and visual cortices [54, 144, 145]. Based on this broad
mechanism of action, topiramate may prevent the development of cortical spread-
ing depression by reducing nociceptive transmission and generally inhibiting neu-
ronal hyperexcitability [146]. Similarly, topiramate has demonstrated cognitive
adverse events, which are likely a reflection of the central inhibitory effects [54].
Pooled analyses of clinical trial results suggest that preventive topiramate treatment
in patients with episodic migraine may reduce the risk of headache-day increase,
which in some cases may prevent migraine chronification [147].
7.3.3 Monoclonal antibodies
Deeper understanding the importance of CGRP and its receptor role in CM
pathophysiology and need for more effective, better tolerated prophylactic thera-
pies for CM or high-frequency EM gave background for the development of the
new class drugs—anti-CGRP/R monoclonal antibodies (mAbs).
Four anti-CGRP/R antibodies are approved in the US and Europe for the pro-
phylactic treatment of CM: erenumab (Aimovig) [148, 149], which targets the
CGRP receptor, fremanezumab (Ajovy) [150, 151] and galcanezumab (Emgality)
[152, 153] which target the CGRP ligand; and fourth anti-CGRP/R antibody against
the CGRP ligand, eptinezumab (VYEPTI™), which was approved by FDA and EMA
on year 2020 [154, 155]. These macromolecule anti-CGRP/R antibodies have been
specifically designed for prophylactic use in CM and frequent EM, and to overcome
safety issues associated with CGRP receptor antagonists [156, 157]. Eptinezumab
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(VYEPTI™) is the first intravenous (IV) treatment for migraine prevention and the
latest in a new class of mAbs. A brief review of all four mAbs, dose and rout of
adminstration are provided in Table 5.
The anti-CGRP/R antibodies are highly specific for their CGRP/R target, have no
ability to cross the blood brain barrier, and bypass liver metabolism so CNS-related
effects and hepatotoxicity are unlikely [158]. Their long half-lives allow for dosing
once a month for erenumab and galcanezumab, or and once every 3months, for
fremanezumab [159–161] and eptinezumab [162].
This very promising treatment with mABs for CM is proved in clinical trials [163].
Erenumab: A phase II RCT evaluated the safety and the efficacy of erenumab in
subjects aged 18–65years with CM with duration of treatment 3 months and pre-
ventive treatment not allowed [164]. Patients (n = 667) were randomized to
monthly subcutaneous injection of erenumab 70mg, erenumab 140mg or placebo
for 3months. Exclusion by preventive failure of >3 drugs. At weeks 9–12, there was
a reduction in monthly migraine days in the erenumab 70mg (LSMD 2.5; SE 3.5
to 1.4; P < 0.0001) and in the erenumab 140mg (LSMD 2.5; SE 3.5 to 1.4; P
< 0.0001) groups compared to placebo group. There was a reduction in monthly
number of days using migraines-specific medication in the erenumab 70mg (LSMD
1.9; SE 2.6 to 1.1; P < 0.0001) and in the erenumab 140mg (LSMD 2.6; SE
3.3 to 1.8; P < 0.0001) groups compared to the placebo group.
Fremanezumab: In this multicentre, randomized, double-blind, double-
dummy, placebo-controlled, parallel-group phase 2b study, were enrolled men and
Drug Manufacturer Target Dose of administration Route of
administration
Dosing
Erenumab
(Aimovig)
Amgen and
Novartis
Pharmaceu-
ticals
CGRP
receptor
70 mg Once monthly Autoinjector
70 mg/mL
140 mg Some patients
may need
140 mg SC
once monthly
Autoinjector
140 mg/mL
Fremanezumab
(Ajovy)
Teva CGRP
ligand
225 mg Once monthly Syringe or
autoinjector
225 mg/
1.5 mL
675 mg Every 3 months
(q)
Galcanezumab
(Emgality
Eli Lilly and
Company
CGRP
ligand
240 mg(2 consecutive
120 mg SC injections)
loading dose once,
maintainance dose
120 mg monthly
Once monthly Single-dose
prefilled pen
120 mg/mL
and single-
dose
prefilled
syringe
100 mg/mL
and 120 mg/
mL
Eptinezumab
(VYEPTI™)
Alder
Biopharma-
ceuticals
and Lundbeck
Seattle
BioPharma-
ceuticals Inc.
CGRP
ligand
100 mg IV every
3 months (q)
Every 3 months
(q)
Injectable
solution
100 mg/ml
300 mg IV every
3 months (q)
Some patients
may benefit
from a 300 mg
IV dose q3
months
Table 5.
Brief review of administration of CRRP/R monoclonal antibodies.
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women (aged 18–65 years) who had CM with duration of treatment 3 months [165].
Patients (n = 264) were randomized to three 28-day treatment cycles of subcutane-
ous injections of fremanezumab 225mg, fremanezumab 900mg or placebo. Exclu-
sion by preventive failure of >3 drugs. At weeks 9–12, there was a reduction in
moderate to severe headache days in the fremanezumab 675/225mg (LSMD 1.84;
95% CI 3.54 to 0.14; P = 0.0345) and in the fremanezumab 900mg (LSMD
1.96; 95% CI 3.66 to 0.26; P = 0.0237) groups compared to placebo group.
There was a reduction in number of days using acute medication in the
fremanezumab 900mg (LSMD 2.04; 95% CI 3.9 to 0.2; P = 0.027) group
compared to placebo group.
A phase III RCT, the HALO CM, evaluated the efficacy of fremanezumab in
subjects aged 18–70years with CM with duration of treatment 3 months [160].
Patients (n = 1130) were randomized to monthly subcutaneous injections of
fremanezumab 225mg (loading dose of 675mg), to quarterly fremanezumab 675
mg, or placebo for 3months. Exclusion by preventive failure of ≥2 drugs. During
12-week period, there was a reduction in the average number of headache days per
month in the fremanezumab 675mg (LSMD 1.8; SE 0.3; P < 0.001) and in the
fremanezumab 675/225mg (LSMD -2.1; SE 0.3; P < 0.001) groups compared to
placebo group. There was a reduction in the monthly number of days using acute
medication in the fremanezumab 675mg (LSMD 1.8; SE 0.3; P < 0.001) and in
the fremanezumab 675/225mg (LSMD2.3; SE 0.3; P < 0.001) groups compared to
placebo group. There was an improvement in the HIT-6 [166] score in the
fremanezumab 675mg (LSMD 1.9; SE 0.5; P < 0.001) and in the fremanezumab
675/225mg (LSMD 2.4; SE 0.5; P < 0.001) groups compared to placebo group.
Galcanezumab: A phase III RCT, the randomized, double-blind, placebo-
controlled REGAIN study evaluated the efficacy of galcanezumab in subjects aged
18–65years with CM with duration of treatment 3 months [161]. Patients (n = 1117)
were randomized to monthly subcutaneous injections of galcanezumab 120mg
(loading dose of 240mg at baseline), galcanezumab 240mg, or placebo for 3
months. Exclusion by preventive failure of >2 drugs During the 3-month period,
there was a reduction in monthly migraine days in the galcanezumab 120mg group
(LSMD 2.1; 95% CI 2.9 to 1.3) and with galcanezumab 240mg (LSMD 1.9;
95% CI 2.7 to 1.1) compared to placebo groups. There was a reduction in
monthly number of days using acute medication use in the galcanezumab 240mg
(LSMD 2.0; 95% CI 2.8 to 1.3) but not in galcanezumab 120mg as compared to
the placebo group. There was an improvement in the MIDAS score in the
galcanezumab 120mg (LSMD8.7; 95% CI 16.4 to3.1) but not in galcanezumab
240mg as compared to the placebo group.
Eptinezumab: This was a phase 2b, parallel-group, double-blind, randomized,
placebo-controlled, dose-ranging clinical trial with duration of treatment 12 weeks
and preventive treatment, except botulin toxin, not allowed [162]. Men and women
aged 18–55 years (n = 616) were included if they had a diagnosis of CMwith onset at
age 35 years and history of CM 1 year. During the 28-day screening period, patients
must have had 15 headache days, including 8 migraine days, with five migraine
attacks as recorded in the electronic diary. Exclusion is by preventive failure of ≥2
drugs. Patients were assigned in a 1:1:1:1:1 ratio to eptinezumab 300, 100, 30, 10 mg
or placebo, administered as a single IV infusion. The primary endpoint was the
percentage of patients with a 75% decrease in monthly migraine days over weeks
1–12 compared with the 28-day screening period. Secondary efficacy endpoints had
results favoring the three higher eptinezumab doses versus placebo. The greatest
effect of eptinezumab, as measured by the HIT-6 was observed at week 12, with
changes in baseline scores of 10.0, 6.9, 6.5, and 6.5 for the 300, 100, 30, and 10 mg
groups, respectively, compared with 5.8 for the placebo group. A prespecified
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analysis of the percentage of patients for whommigraine had a severe impact on life
demonstrated a reduction from 90.3% at baseline to 29.9% at week 12 with
eptinezumab 300 mg, 86.4–43.0% with eptinezumab 100 mg, compared with
79.3–50.9% with placebo.
The Prevention of Migraine via Intravenous ALD403 Safety and Efficacy–2
(PROMISE-2) study was a phase 3, multicenter, randomized, double-blind,
placebo-controlled, parallel-group study with duration of treatment 12 weeks [167].
Adults with CM (n = 1072) were randomly assigned to receive IV eptinezumab
100 mg, eptinezumab 300 mg, or placebo administered on day 0 and week 12.
Exclusion is by preventive failure of ≥2 drugs. The primary endpoint was change
from baseline in mean monthly migraine days (MMDs) over weeks 1–12. Treatment
with eptinezumab 100 and 300 mg was associated with significant reductions in
MMDs across weeks 1–12 compared with placebo (placebo 5.6, 100 mg 7.7,
p < 0.0001 vs. placebo; 300 mg 8.2, p < 0.0001 vs. placebo). The mean HIT-6
scores at baseline were 65.0 (eptinezumab 100 mg), 65.1 (eptinezumab 300 mg),
and 64.8 (placebo). By week 12, the percentage of patients with HIT-6 scores in the
severe range had been reduced to 51.4% in the eptinezumab 100 mg treatment
group, 42.9% in the eptinezumab 300 mg treatment group, and 60.1% in the
placebo group. Patients in the eptinezumab 300 mg group demonstrated a statisti-
cally significant improvement on the HIT-6 at week 12, with an estimated
mean difference from placebo (95% confidence interval) of 2.9 (3.9 to 1.8,
p < 0.0001).
Adverse events of the mAbs: The results of four mABs clinical studies showed
that no serious advers events (SAEs), no deaths deemed to be related to mAbs
occurred in clinical trials with all fours mAbs. According the data of clinical trials,
the most common adverse events (5 to >10% of the study population) for all three
CGRP antagonists (erenumab, fremanezumab, galcanezumab) were injection-site
reactions and pain. Specific adverse reactions for erenumab was constipation (1–3%
of patients) and cramps, muscle spasms (<3%), hyperintensity for galcanezumab,
and nasopharyngitis (6–8%) and hyperintensity (1–2%) for eptinezumab.
Recommendations on the use of the mAbs: Following the clinical studies
results and expert opinion EHF on 2019 prepared recommendations about the use
three mAbs (erenumab, fremanezumab, galcanezumab) in subjects with CM [163].
In these recommendations due to the then-unpublished original data eptinezumab
was not included (Table 6). Keeping in mind the fact that this mAb belongs to the
same class of drugs (e.g., anti-calcitonin gene-related peptide monoclonal anti-
bodies) with similar profile it seems that the recommendations fits for it too.
7.3.4 Combinations
The strategy of combining different prophylactic drugs is not supported by high-
level evidence [168]. However, the so-called rational polytherapy—the association
of effective drugs with different mechanisms—can be used in monotherapy-
refractory patients [169]. Regarding comparative efficacy, one single-center
double-blind RCT showed equivalence between OBT-A (100 units at fixed points
plus 100 units at “follow the pain” points) and topiramate (maximum dose of
200 mg), with better tolerability and adherence in the OBT-A [121] while one
single-center open-label study showed comparable efficacy between amitriptyline
(25–50 mg/day) and OBT-A (250 U/15 sites), also with better tolerability and
compliance in the group treated with OBT-A [122].
Preclinical data suggest that anti-calcitonin gene-related peptide monoclonal
antibodies and OBT-A have synergistic effects within the trigeminovascular system.
Of note, findings indicate that fremanezumab—an antibody targeting the calcitonin
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gene-related peptide—mainly prevents the activation of Aδ-fibers, whereas botuli-
num toxin type A prevents the activation of C-fibers [168]. There is currently only
indirect preclinical evidence to support a rationale for dual therapy with anti-
calcitonin gene-related peptide monoclonal antibodies and OBT-A for CM preven-
tion [170]. Rigorous studies evaluating clinical efficacy, safety, and cost-
effectiveness of dual therapy with mAbs are needed.
Clinical
question
Recommendation Strength of the
recommendation
1. When should treatment with anti-CGRP monoclonal antibodies be offered to patients with
migraine?
In patients with CM who have failed at least two of the available
medical treatments or who cannot use other preventive treatments
because of comorbidities, side effects or poor compliance, we
suggest the use of erenumab, fremanezumab, or galcanezumab
Experts’ opinion
2. How should other preventive treatments be managed when using anti-CGRP monoclonal antibodies
in patients with migraine?
In patients with CM who are on treatment with any oral drug with
inadequate treatment response we suggest to add erenumab,
fremanezumab, or galcanezumab and to consider later withdrawal of
the oral drug
In patients with chronic migraine who are on treatment with OBT-A
with inadequate treatment response we suggest to stop OBT-A
before initiation of erenumab, fremanezumab, or galcanezumab
In patients with CM who are on treatment with erenumab,
fremanezumab, or galcanezumab and who may benefit from
additional prevention we suggest to add oral preventive drugs
Experts’ opinion
3. When should treatment with anti-CGRP monoclonal antibodies be stopped in patients with
migraine?
In patients with CM, we suggest to consider to stop treatment with
erenumab, fremanezumab, and galcanezumab after 6–12months of
treatments
Experts’ opinion
4. Should medication overuse be treated before offering treatment anti-CGRP monoclonal antibodies
to patients with chronic migraine?
In patients with CM and medication overuse, we suggest to use
erenumab, fremanezumab, and galcanezumab before or after
withdrawal of acute medications
Experts’ opinion
5. In which patients anti-CGRP monoclonal antibodies are not to be used?
In patients with migraine, we suggest to avoid anti-CGRP
monoclonal antibodies in pregnant or nursing women, in individuals
with alcohol or drug abuse, cardio and cerebrovascular diseases, and
with severe mental disorders
Experts’ opinion
6. Should binding and/or neutralizing antibodies be monitored?
In patients with migraine on treatment with anti-CGRP
monoclonal antibodies, we suggest not to test binding and/or
neutralizing antibodies in daily clinical practice; we suggest to
further study the possible implications of binding and/or
neutralizing antibodies
Experts’ opinion
*Adapted with permission: Sacco et al. [163].
Table 6.
Recommendations on use of anti-calcitonin gene-related peptide monoclonal antibodies in subjects with chronic
migraine*.
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8. Management of chronic migraine
CM is underdiagnosed and, thus, untreated disease. Only 20% of patients who
meet the criteria for CM are properly diagnosed [65].Treatment options are avail-
able for these patients, but only if the patients are properly identified [171]. Suc-
cessful management of CM will help properly diagnose this disease, optimize
treatment and thus reduce the global burden of it. Important components of CM
management involve correct diagnosis, optimal treatment plan, patient education,
treatment of MOH and comorbid conditions and monitoring of patients response to
treatment plan.
It is important for all physicians who are treating the patient to understand the
treatment plan, in order to monitor the patient’s response to treatment, using as
well as continual assessment of the patient’s Health-Related Quality of Life
(HRQOL) [95]. Preventive therapy for migraines may take up to 6–8 weeks to begin
to demonstrate efficacy, and up to 6 months before full efficacy is established [172].
Support and close follow-up are essential for patients, particularly in the first
3 months of treatment [172].
Additionally, physicians should try to identify and reduce aggravating risk fac-
tors, such as triggers of migraine or other behavioral habits that may have contrib-
uted to the patient’s headaches (Section 7.1).
Thus, multimodal treatment concepts are superior to simple drug treatment in
severely affected patients [95].
Box 1 contains the key components of chronic migraine management for physi-
cians [95].
9. Conclusions
CM is associated with higher burden of disease, more severe psychiatric comor-
bidity, greater use of healthcare resources, and higher total costs than EM. The
current definition of CM has gone through multiple revisions, but the discussion
about it is still continuing,
Complete and correct diagnosis
Referral to headache specialist/neurologist to confirm CM diagnosis and provide a treatment plan
Management of overuse of acute headache pain medications: providing limits to acute and rescue
therapy
Patient education about CM and importance of treatment compliance
Explaining realistic expectations to patients
Consideration of important exacerbating factors
Treatment of comorbid conditions
Nonpharmacotherapy, including trigger management and behavioral therapy
CM, chronic migraine; HIT-6, headache impact test-6; HRQoL, health-related quality of life; MIDAS, migraine
disability assessment.
*With permission: Diener et al. [95].
Box 1.
Important components of chronic migraine management*.
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The pathophysiology of CM is not fully understood. However, recent advances
in electrophysiology and neuroimaging have indicated that atypical pain processing,
central sensitization, cortical hyperexcitability and neurogenic inflammation are
important in the development of this disorder. The most significant risk factors
such as overuse of acute medication, ineffective acute treatment, obesity, depres-
sion and stressful life events have been associated with migraine progression.
Unfortunately, CM is still undertreated because of its poor treatment response
and limited therapy options. The currently available evidence-based prophylactic
treatment options for CM are topiramate and OBT-A. According to the results of the
clinical studies the new class of drugs—anti-CGRP/R monoclonal antibodies seems
to be a very promising treatment for CM. Complete and correct diagnosis, optimal
treatment plan, management of acute medication overuse and exacerbating factors,
patient education and monitoring of the patient’s response to treatment plan are the
most important components for the successful CM management.
The next years seem to be inspiring for the field, as current research areas are
being extended and novel areas are being covered, ultimately broadening our
understanding of the complex syndrome of CM.
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Abbreviations
CM chronic migraine
HIS the International Headache Society
EM episodic migraine
MIDAS Migraine Disability Assessment
ICHD-3 International Classification of Headache Disorders, 3rd edition
ICHD-1 International Classification of Headache Disorders, 1st edition
ICHD-2 Classification of Headache Disorders, 2nd edition
MOH medication-overuse headache
CSD cortical spreading depression
VIP vasoactive intestinal peptide
CGRP calcitonin gene-related peptide
HIT-6 Headache Impact Test-6
5HT1 serotonin 1a
OBT-A onabotulinumtoxinA
FDA U.S. Food & Drug Administration
EMA European Medicines Agency
HRQoL health-related quality of life
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